Advertisement

Article | 2026 Clinical Trials at the Summit

New Therapy Combines Wnt Activation and VEGF Inhibition

SZN-8141 is designed to activate Wnt signaling while inhibiting VEGF, bringing 2 therapeutic mechanisms into a single molecule.

By: Daniel Chao, MD, Diana V. Do, MD
Retinal Physician June 24, 2026
Objective:

To discuss the novel therapy SZN-8141 designed for diabetic macular edema and retinal vascular diseases.

Approach:
  • Therapeutic Mechanism: SZN-8141 activates Wnt signaling while inhibiting VEGF, combining two therapeutic mechanisms into a single molecule.
Key Findings:
  • SZN-8141 shows superior efficacy compared to monotherapy.
Interpretation:

Limitations:
  • Clinical trials have not yet commenced in humans.
Conclusion: